Assessing nerve damage from chemotherapy in cancer patients
Evaluation of Chemotherapy Induced Neuropathy in Solid Cancer Patients
This study is testing how chemotherapy affects nerve health in cancer patients by looking at symptoms and certain vitamin levels before and after their treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 124 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Swami Rama Himalayan University Academic / other |
| Drugs / interventions | chemotherapy, Radiation |
| Locations | 1 site (Dehradun) |
| Trial ID | NCT06491082 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the severity of chemotherapy-induced peripheral neuropathy (CIPN) in patients with solid cancers such as head and neck, breast, and prostate. Participants will undergo nerve conduction tests and assessments of vitamin D, vitamin B12, and NADPH oxidase 4 (NOX4) expression before and after their fourth cycle of chemotherapy. The study will track changes in neuropathy symptoms and biochemical markers to understand the impact of chemotherapy on nerve health. The findings may help identify risk factors and improve management strategies for CIPN.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old who are scheduled to receive at least four cycles of chemotherapy for solid tumors.
Not a fit: Patients with pre-existing neuropathy, psychiatric illnesses, or significant comorbid conditions such as long-standing diabetes or renal and hepatic disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better understanding and management of chemotherapy-induced neuropathy, improving quality of life for cancer patients.
How similar studies have performed: While there have been studies on chemotherapy-induced neuropathy, this specific approach focusing on biochemical markers and gene expression is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients receiving chemotherapy for solid cancer * Patient aged\>18years Exclusion Criteria: * Age ≤ 18 years * Pre-existing neuropathy * Patients diagnosed with Psychiatric illness * Patients with pre-existing peripheral neuropathy * Patients taking medication for neuropathy * Long standing diabetes (\>10 years) * Renal and Hepatic disease
Where this trial is running
Dehradun
- Himalayan Hospital(Cancer Research Institute), Himalayan Institute of Medical Sciences — Dehradun, India (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.